{"protocolSection": {"identificationModule": {"nctId": "NCT00931710", "orgStudyIdInfo": {"id": "CVEA489AUS01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension", "officialTitle": "A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension", "acronym": "EXALT"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-07"}, "primaryCompletionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-01", "studyFirstSubmitQcDate": "2009-07-01", "studyFirstPostDateStruct": {"date": "2009-07-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-13", "resultsFirstSubmitQcDate": "2011-01-13", "resultsFirstPostDateStruct": {"date": "2011-02-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-01", "lastUpdatePostDateStruct": {"date": "2011-03-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg)."}, "conditionsModule": {"conditions": ["Stage 2 Systolic Hypertension"], "keywords": ["Hypertension", "combination therapy", "valsartan", "cardiovascular diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 488, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/amlodipine/HCTZ", "type": "EXPERIMENTAL", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.", "interventionNames": ["Drug: valsartan, amlodipine, HCTZ"]}, {"label": "Losartan/HCTZ", "type": "ACTIVE_COMPARATOR", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.", "interventionNames": ["Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ"]}], "interventions": [{"type": "DRUG", "name": "valsartan, amlodipine, HCTZ", "description": "combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study", "armGroupLabels": ["Valsartan/amlodipine/HCTZ"]}, {"type": "DRUG", "name": "Losartan, HCTZ followed by valsartan, amlodipine, HCTZ", "description": "losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study", "armGroupLabels": ["Losartan/HCTZ"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure After 6 Weeks", "description": "To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "Baseline to Week 6"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks", "description": "To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "Baseline to Week 6"}, {"measure": "Cumulative Percentage of Patients Achieving Blood Pressure Control", "description": "To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \\< 140 mmHg and MSDBP \\< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "3 and 6 weeks"}, {"measure": "Cumulative Percentage of Treatment Responders", "description": "To compare the percentage of treatment responders (defined as patients with MSSBP \\< 140 mmHg or demonstrating a decrease from baseline of \u2265 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "3 and 6 weeks"}, {"measure": "Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks", "description": "To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "Baseline to week 12"}, {"measure": "Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit", "description": "To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.", "timeFrame": "3, 6, 9 and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatient of 18 years of age or greater\n* Stage 2 systolic hypertension defined as office Mean Sitting Systolic blood pressure (MSSBP) greater than or equal to 160 and \\< 200 mmHg at randomization\n* Patients who were able to participate in the study, and who gave written informed consent before any study assessment was performed.\n\nExclusion Criteria:\n\n* Office systolic blood pressure \\>200 and/or mean sitting diastolic blood pressure (MSDBP) greater than or equal to 110 mmHg at Visit 1.\n* Use of four (4) or more antihypertensive medications within 30 days of Visit 1.\n* Refractory hypertension, defined as blood pressure \\>140/90 mmHg while taking three (3) drugs at the maximum dose of each drug, one of which must be a diuretic. (Therapy with a fixed-dose combination of two active medications represents two drugs).\n* Inability to safely discontinue all antihypertensive medications for 1-2 weeks prior to randomization.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "862-778-8300", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "sites in USA", "city": "East Hanover", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "FG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "241"}, {"groupId": "FG001", "numSubjects": "247"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "207"}, {"groupId": "FG001", "numSubjects": "209"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "38"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Abnormal test procedure results", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effects", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "BG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "241"}, {"groupId": "BG001", "value": "247"}, {"groupId": "BG002", "value": "488"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.0", "spread": "9.83"}, {"groupId": "BG001", "value": "57.1", "spread": "9.69"}, {"groupId": "BG002", "value": "56.1", "spread": "9.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "213"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "139"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "275"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure After 6 Weeks", "description": "To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS). Last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 6", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "166.8", "spread": "7.03"}, {"groupId": "OG001", "value": "168.5", "spread": "9.03"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "135.5", "spread": "16.26"}, {"groupId": "OG001", "value": "142.5", "spread": "18.89"}]}]}, {"title": "Change from Baseline to Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.3", "spread": "15.87"}, {"groupId": "OG001", "value": "-26.0", "spread": "16.62"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks", "description": "To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS). Last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 6", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.6", "spread": "7.71"}, {"groupId": "OG001", "value": "97.6", "spread": "7.88"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "85.1", "spread": "10.05"}, {"groupId": "OG001", "value": "88.5", "spread": "11.36"}]}]}, {"title": "Change from Baseline to Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.6", "spread": "9.48"}, {"groupId": "OG001", "value": "-9.1", "spread": "10.03"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Percentage of Patients Achieving Blood Pressure Control", "description": "To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \\< 140 mmHg and MSDBP \\< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "cumulative percentage of patients", "timeFrame": "3 and 6 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.5"}, {"groupId": "OG001", "value": "15.3"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.5"}, {"groupId": "OG001", "value": "47.1"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Percentage of Treatment Responders", "description": "To compare the percentage of treatment responders (defined as patients with MSSBP \\< 140 mmHg or demonstrating a decrease from baseline of \u2265 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Cumulative percentage of responders", "timeFrame": "3 and 6 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.3"}, {"groupId": "OG001", "value": "34.3"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.0"}, {"groupId": "OG001", "value": "71.5"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks", "description": "To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS). Last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to week 12", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Baseline MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "166.8", "spread": "7.03"}, {"groupId": "OG001", "value": "168.5", "spread": "9.03"}]}]}, {"title": "Week 12 MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.8", "spread": "16.22"}, {"groupId": "OG001", "value": "134.3", "spread": "19.41"}]}]}, {"title": "Change in MSSBP from baseline to Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.0", "spread": "16.08"}, {"groupId": "OG001", "value": "-34.2", "spread": "17.69"}]}]}, {"title": "Baseline MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.6", "spread": "7.71"}, {"groupId": "OG001", "value": "97.6", "spread": "7.88"}]}]}, {"title": "Week 12 MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.5", "spread": "10.18"}, {"groupId": "OG001", "value": "82.5", "spread": "11.43"}]}]}, {"title": "Change in MSDBP from baseline to Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.1", "spread": "9.91"}, {"groupId": "OG001", "value": "-15.1", "spread": "10.57"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit", "description": "To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.", "populationDescription": "Full Analysis Set (FAS).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "cumulative percentage of patients", "timeFrame": "3, 6, 9 and 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine/HCTZ", "description": "Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study."}, {"id": "OG001", "title": "Losartan/HCTZ", "description": "Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force-titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "241"}, {"groupId": "OG001", "value": "247"}]}], "classes": [{"title": "Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8"}, {"groupId": "OG001", "value": "0.8"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8"}, {"groupId": "OG001", "value": "0.8"}]}]}, {"title": "Week 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "0.8"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9"}, {"groupId": "OG001", "value": "4.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan / Amlodipine / HCTZ", "description": "Valsartan / amlodipine / HCTZ", "seriousNumAffected": 1, "seriousNumAtRisk": 241, "otherNumAffected": 13, "otherNumAtRisk": 241}, {"id": "EG001", "title": "Losartan / HCTZ", "description": "Losartan / HCTZ", "seriousNumAffected": 2, "seriousNumAtRisk": 247, "otherNumAffected": 8, "otherNumAtRisk": 247}], "seriousEvents": [{"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 241}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 247}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 241}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 247}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 241}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 247}]}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 241}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 247}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000092244", "term": "Isolated Systolic Hypertension"}, {"id": "D000054160", "term": "Systolic Murmurs"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006337", "term": "Heart Murmurs"}, {"id": "D000075222", "term": "Essential Hypertension"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "asFound": "Systolic", "relevance": "HIGH"}, {"id": "M2913", "name": "Isolated Systolic Hypertension", "asFound": "Systolic Hypertension", "relevance": "HIGH"}, {"id": "M9425", "name": "Heart Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "CRC", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}